Biomarin Historical Cash Flow
| BMRN Stock | USD 66.03 0.61 0.93% |
Analysis of Biomarin Pharmaceutical cash flow over time is an excellent tool to project Biomarin Pharmaceutical future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Free Cash Flow of 54.2 M or Begin Period Cash Flow of 760.8 M as it is a great indicator of Biomarin Pharmaceutical ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Biomarin Pharmaceutical latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Biomarin Pharmaceutical is a good buy for the upcoming year.
Biomarin |
About Biomarin Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Biomarin balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Biomarin's non-liquid assets can be easily converted into cash.
Biomarin Pharmaceutical Cash Flow Chart
Add Fundamental
Change To Inventory
The increase or decrease in the amount of inventory a company has over a certain period.Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Depreciation
Depreciation indicates how much of Biomarin Pharmaceutical value has been used up. For tax purposes Biomarin Pharmaceutical can deduct the cost of the tangible assets it purchases as business expenses. However, Biomarin Pharmaceutical must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.Capital Expenditures
Capital Expenditures are funds used by Biomarin Pharmaceutical to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Biomarin Pharmaceutical operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Biomarin Pharmaceutical's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Biomarin Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.At this time, Biomarin Pharmaceutical's Net Income is very stable compared to the past year. As of the 1st of December 2024, End Period Cash Flow is likely to grow to about 792.9 M, though Change To Inventory is likely to grow to (149.2 M).
Biomarin Pharmaceutical cash flow statement Correlations
Click cells to compare fundamentals
Biomarin Pharmaceutical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Biomarin Pharmaceutical cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (107.6M) | (61.2M) | (35.1M) | (68.3M) | (157.1M) | (149.2M) | |
| Change In Cash | (56.5M) | 211.7M | (61.9M) | 137.3M | 30.6M | 31.7M | |
| Free Cash Flow | (115.1M) | (52.2M) | 185.3M | 44.4M | 51.6M | 54.2M | |
| Change In Working Capital | (101.1M) | (224.4M) | 66.0M | (96.4M) | (336.5M) | (319.7M) | |
| Begin Period Cash Flow | 494.0M | 437.4M | 649.2M | 587.3M | 724.5M | 760.8M | |
| Other Cashflows From Financing Activities | (47.4M) | 27.3M | 3.0M | (16.0M) | (85.8M) | (81.5M) | |
| Depreciation | 105.3M | 105.2M | 108.0M | 102.0M | 104.4M | 109.6M | |
| Other Non Cash Items | (9.2M) | 44.7M | 12.9M | (115.5M) | 61.6M | 64.7M | |
| Capital Expenditures | 163.4M | 137.5M | 119.2M | 131.5M | 107.6M | 88.6M | |
| Total Cash From Operating Activities | 48.3M | 85.4M | 304.5M | 175.9M | 159.3M | 167.2M | |
| Net Income | (23.8M) | 859.1M | (64.1M) | 141.6M | 167.6M | 176.0M | |
| Total Cash From Financing Activities | (74.7M) | 181.1M | (48K) | (18.7M) | (18.7M) | (17.8M) | |
| End Period Cash Flow | 437.4M | 649.2M | 587.3M | 724.5M | 755.1M | 792.9M | |
| Change To Liabilities | 80.2M | (93.9M) | 12.4M | 59.0M | 67.9M | 71.3M | |
| Total Cashflows From Investing Activities | (31.0M) | (53.6M) | (366.3M) | (20.0M) | (18.0M) | (18.9M) | |
| Sale Purchase Of Stock | (42.7M) | (50M) | (45.8M) | (54.3M) | (76.3M) | (72.5M) | |
| Other Cashflows From Investing Activities | 5.8M | 34.5M | (24.6M) | 103.3M | 118.8M | 124.8M | |
| Stock Based Compensation | 159.9M | 189.7M | 197.3M | 196.3M | 207.1M | 126.1M | |
| Change To Account Receivables | (37.9M) | (59.0M) | 65.6M | (82.0M) | (190.4M) | (180.9M) | |
| Investments | 108.2M | 26.2M | (366.3M) | (20.0M) | (101.0M) | (106.0M) | |
| Change Receivables | (54.3M) | (37.9M) | (59.0M) | 65.6M | 75.4M | 79.2M | |
| Net Borrowings | (5.1M) | 210.8M | (3.0M) | (2.6M) | (2.3M) | (2.2M) | |
| Cash And Cash Equivalents Changes | (104.0M) | (56.5M) | 211.7M | (61.9M) | (55.7M) | (52.9M) | |
| Cash Flows Other Operating | (18.7M) | (36.6M) | (10.3M) | 23.2M | 20.9M | 21.9M | |
| Change To Netincome | 56.7M | (671.6M) | 185.2M | 28.8M | 25.9M | 27.2M | |
| Change To Operating Activities | (32.8M) | (17.2M) | 19.8M | (5.1M) | (4.6M) | (4.8M) | |
| Exchange Rate Changes | (598K) | 902K | (1.2M) | (57K) | (65.6K) | (68.8K) |
Pair Trading with Biomarin Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biomarin Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biomarin Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving against Biomarin Stock
| 0.87 | BHC | Bausch Health Companies | PairCorr |
| 0.79 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.77 | GILD | Gilead Sciences | PairCorr |
| 0.72 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.57 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
The ability to find closely correlated positions to Biomarin Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biomarin Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biomarin Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biomarin Pharmaceutical to buy it.
The correlation of Biomarin Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biomarin Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biomarin Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biomarin Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.607 | Earnings Share 1.66 | Revenue Per Share 14.529 | Quarterly Revenue Growth 0.283 | Return On Assets 0.03 |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.